Who are Abciximab; reteplase; abciximab placebo; abciximab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): abciximab bolus only regimen, abciximab intracoronary, Abciximab + UFH, Tirofiban+Oral Dual Antiplatelet Therapy, Bivalirudin with and without eptifibatide, clopidogrel/abciximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abciximab-reteplase-abciximab-placebo-abciximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Abciximab; reteplase; abciximab placebo; abciximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abciximab; reteplase; abciximab placebo; abciximab (Abciximab; reteplase; abciximab placebo; abciximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycoprotein IIb/IIIa inhibitor. Area: Cardiovascular.

phase 3 Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa integrin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Abciximab; reteplase; abciximab placebo; abciximab (Abciximab; reteplase; abciximab placebo; abciximab) — Centocor, Inc.. Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Abciximab; reteplase; abciximab placebo; abciximab TARGET	Abciximab; reteplase; abciximab placebo; abciximab	Centocor, Inc.	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa integrin receptor
abciximab bolus only regimen	abciximab bolus only regimen	Università degli Studi di Ferrara	marketed	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa integrin receptor
abciximab intracoronary	abciximab intracoronary	University of Leipzig	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa integrin receptor
Abciximab + UFH	Abciximab + UFH	Deutsches Herzzentrum Muenchen	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor
Tirofiban+Oral Dual Antiplatelet Therapy	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
Bivalirudin with and without eptifibatide	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
clopidogrel/abciximab	clopidogrel/abciximab	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor)	P2Y12 receptor (clopidogrel); glycoprotein IIb/IIIa integrin (abciximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycoprotein IIb/IIIa inhibitor class)

Beijing Tiantan Hospital · 1 drug in this class
Centocor, Inc. · 1 drug in this class
General Hospital of Shenyang Military Region · 1 drug in this class
Ministry of Science and Technology of the People´s Republic of China · 1 drug in this class
Organon and Co · 1 drug in this class
Ottawa Heart Institute Research Corporation · 1 drug in this class
University of Leipzig · 1 drug in this class
University of Luebeck · 1 drug in this class
Università degli Studi di Ferrara · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abciximab; reteplase; abciximab placebo; abciximab — Competitive Intelligence Brief. https://druglandscape.com/ci/abciximab-reteplase-abciximab-placebo-abciximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab